Fundraisings and IPOs

Date: 2022-03-30

Type of information: Loan

Company: Vectivbio (Switzerland)

Investors: Kreos Capital (UK)

Amount: up to a $75 million

Funding type: loan

Planned used:


* On March 30, 2022, VectivBio, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, has entered into a loan facility with Kreos Capital, a leading global growth lender to life sciences and healthcare companies, granting it access of up to a $75 million flexible loan facility with a minimum required drawdown of $10 million.

Therapeutic area: Inflammatory diseases - Gastrointestinal diseases - Transplantation

Is general: Yes